Effect of Cholecalciferol Supplementation on the Clinical Features and Inflammatory Markers in Hospitalized COVID-19 Patients: A Randomized, Open-Label, Single-Center Study
Karonova TL, Golovatyuk KA, Kudryavtsev IV, Chernikova AT, Mikhaylova AA, Aquino AD, Lagutina DI, Zaikova EK, Kalinina OV, Golovkin AS, Grant WB, Shlyakhto EV
Nutrients · 32 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Ministry of Science and Higher Education of the Russian Federation
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- Ministry of Science and Higher Education of the Russian Federation (075‐15‐2022‐301)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2022-06-23 · Nutrients · vol. 14 · número 13 · pág. 2602
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 40 citas · más que el 96% de estudios similares · 4.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 59 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · Dermatological and COVID-19 studies
- Palabras clave
- Cholecalciferol, Medicine, Gastroenterology, Internal medicine, Coronavirus disease 2019 (COVID-19), Vitamin D and neurology, Randomized controlled trial
- MeSH
- humans, vitamin d deficiency, cholecalciferol, vitamin d, dietary supplements, biomarkers, covid-19 drug treatment
12 autores
- Т. Л. Каронова🇷🇺 · autor de correspondenciaFederal Almazov North-West Medical Research Centre
- Ksenia A. Golovatyuk🇷🇺Federal Almazov North-West Medical Research Centre
- Igor Vladimirovich Kudryavtsev🇷🇺Federal Almazov North-West Medical Research Centre; Institute of Experimental Medicine
- Alena T. Chernikova🇷🇺Federal Almazov North-West Medical Research Centre
- Arina A. Mikhaylova🇷🇺Federal Almazov North-West Medical Research Centre
- Arthur D. Aquino🇷🇺Federal Almazov North-West Medical Research Centre
- Daria I. Lagutina🇷🇺Federal Almazov North-West Medical Research Centre
- Ekaterina Konstantinovna Zaikova🇷🇺Federal Almazov North-West Medical Research Centre
- Olga Kalinina🇷🇺Federal Almazov North-West Medical Research Centre
- А. С. Головкин🇷🇺Federal Almazov North-West Medical Research Centre
- William Burgess Grant🇺🇸Sunlight Nutrition and Health Research Center
- Evgeny V. Shlyakhto🇷🇺Federal Almazov North-West Medical Research Centre
Resumen
El texto original del estudio, en el idioma en que se publicó.
Recent studies showed that a low 25-hydroxyvitamin D (25(OH)D) level was associated with a higher risk of morbidity and severe course of COVID-19. Our study aimed to evaluate the effects of cholecalciferol supplementation on the clinical features and inflammatory markers in patients with COVID-19. A serum 25(OH)D level was determined in 311 COVID-19 patients. Among them, 129 patients were then randomized into two groups with similar concomitant medication. Group I (n = 56) received a bolus of cholecalciferol at a dose of 50,000 IU on the first and the eighth days of hospitalization. Patients from Group II (n = 54) did not receive the supplementation. We found significant differences between groups with the preferential increase in serum 25(OH)D level and Δ 25(OH)D in Group I on the ninth day of hospitalization (p < 0.001). The serum 25(OH)D level on the ninth day was negatively associated with the number of bed days (r = −0.23, p = 0.006); we did not observe other clinical benefits in patients receiving an oral bolus of cholecalciferol. Moreover, in Group I, neutrophil and lymphocyte counts were significantly higher (p = 0.04; p = 0.02), while the C-reactive protein level was significantly lower on the ninth day of hospitalization (p = 0.02). Patients with supplementation of 100,000 IU of cholecalciferol, compared to those without supplementation, showed a decrease in the frequencies of CD38++CD27 transitional and CD27−CD38+ mature naive B cells (p = 0.006 and p = 0.02) and an increase in the level of CD27−CD38− DN B cells (p = 0.02). Thus, the rise in serum 25(OH)D level caused by vitamin D supplementation in vitamin D insufficient and deficient patients may positively affect immune status and hence the course of COVID-19.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.